Jasper Therapeutics, Inc. has recently disclosed a notable investment from Affinity Asset Advisors, LLC and its managing member, Michael Cho. This investment, amounting to 1,850,000 shares or approximately 5.6% of the total shares outstanding, was reported in a Schedule 13G filing with the SEC on November 13, 2026. This development is significant as it underscores growing interest in the biological products sector, particularly amid ongoing advancements in biotechnology.

Jasper Therapeutics, Inc. is classified under the SIC code 2836, which pertains to Biological Products, (No Diagnostic Substances). The company operates on the Nasdaq exchange under the ticker symbol JSPR. As an emerging growth company, Jasper Therapeutics focuses on innovative therapies and products that address unmet medical needs.

The recent SEC filing indicates that Affinity Asset Advisors, LLC and Michael Cho beneficially own 1,850,000 shares of Jasper Therapeutics' common stock. The filing states, "As of September 30, 2026, the Reporting Persons beneficially own approximately 5.6% of the Common Stock outstanding." This percentage is based on 33,274,561 shares of common stock reported as outstanding in Jasper's Definitive Proxy Statement filed on October 19, 2026.

This stake is notable as it positions Affinity Asset Advisors and Cho among the significant shareholders of Jasper Therapeutics. Their investment may influence the company's strategic decisions and could also signal to other investors the potential growth and opportunities within the biological products market.

The implications of this investment extend beyond Jasper Therapeutics. The biological products industry is characterized by rapid innovation and competition, with various companies vying for market share. The presence of a substantial investor like Affinity Asset Advisors could prompt other firms in the sector to evaluate their own investment strategies and shareholder structures.

While the filing does not specify the next steps following this disclosure, it highlights the increasing attention that Jasper Therapeutics is garnering from institutional investors. This interest could lead to further developments, including potential collaborations, partnerships, or additional investments in the future.